EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Formulation Engineering of Oral Semaglutide Tablets: Unleashing Gastric Intestinal Permeation with Sodium Caprate

Do-Hyub Kim, Sung-Kwan Hwang, Ji-Hyeon Yoon, Dong Hee Na iD, Young-Joon Park iD, Yoon-Jee Chae iD, Ji-Eun Chang iD, Joo-Eun Kim iD

Pharmaceutics · 29.05.2026 · 18 (6) · 680

DOI: 10.3390/pharmaceutics18060680 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 29.05.2026. Verfasst von Do-Hyub Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biopharmaceutical Chemistry, Kookmin University, Seoul 02707, Republic of Korea. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Trade, Industry and Energy, Ministry of Trade, Industry and Energy (MOTIE), Republic of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Oral delivery of semaglutide (Rybelsus) relies on sodium N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC) to enhance peptide absorption. However, formulation constraints and SNAC’s localized gastric mechanism have prompted the exploration of alternative enhancers. This study evaluated whether sodium caprate (C10), a well-characterized medium-chain fatty acid (MCFA), could achieve systemic exposure comparable to SNAC-based formulations when co-formulated in an immediate-release (IR) tablet.

Methods

Preformulation studies assessed the physicochemical properties and buffering capacity of C10. Mechanistic feasibility was evaluated through Caco-2 transport studies and rat pharmacokinetic (PK) trials using aqueous suspensions, comparing the concentration-dependent effects of C10 and SNAC. Based on these findings, three IR tablet architectures (monolayer, bilayer, and dry compression-coated) were developed. The optimized formulation was evaluated in beagle dogs (14 mg semaglutide) and compared with the SNAC-based reference product.

Results

C10 exhibited sufficient buffering capacity to neutralize acidic environments. In Caco-2 and rat PK studies, C10 enhanced semaglutide absorption in a concentration-dependent manner, yielding exposure levels equivalent to SNAC at matched doses. Among the tablet designs, the monolayer tablet showed the highest dissolution similarity (f2 = 67.8) to Rybelsus. In beagle dogs, the optimized monolayer formulation produced pharmacokinetic parameters, including Cmax, AUClast, and t1/2, that overlapped with those of the SNAC-based reference drug product under matched dosing conditions.

Conclusions

These results demonstrate that C10 can effectively support oral semaglutide delivery when incorporated into a rationally designed IR tablet. The findings support the feasibility of MCFA-based permeation enhancer platforms as formulation alternatives to SNAC for oral peptide therapeutics.

Schlagwörter

Stichwörter der Autor:innen

C10 enhancerGLP-1oral formulationoral peptide deliverypharmacokineticssemaglutidesodium caprate

Autor:innen und Institutionen

  • Department of Biopharmaceutical Chemistry, Kookmin University, Seoul 02707, Republic of Korea.
  • MFC Co., Ltd., 35 Cheongwonsandan 7-gil, Mado-myeon, Hwaseong-si 18543, Republic of Korea.
  • College of Pharmacy, Chung-Ang University, Seoul 06974, Republic of Korea.
  • College of Pharmacy, Ajou University, Suwon-si 16499, Republic of Korea.
  • Department of Pharmacology, College of Medicine, Konyang University, Daejeon 35365, Republic of Korea.
  • College of Pharmacy, Dongduk Women's University, Seoul 02748, Republic of Korea.

ORCID-Profile: Dong Hee Na, Young-Joon Park, Yoon-Jee Chae, Ji-Eun Chang, Joo-Eun Kim

Förderung

  • Ministry of Trade, Industry and Energy
  • Ministry of Trade, Industry and Energy (MOTIE), Republic of Korea

Zitieren

APA

Kim, D. H., Hwang, S. K., Yoon, J. H., Na, D. H., Park, Y. J., Chae, Y. J., Chang, J. E., & Kim, J. E. (2026). Formulation Engineering of Oral Semaglutide Tablets: Unleashing Gastric Intestinal Permeation with Sodium Caprate. Pharmaceutics, 18(6), 680. https://doi.org/10.3390/pharmaceutics18060680

Vancouver

Kim DH, Hwang SK, Yoon JH, Na DH, Park YJ, Chae YJ, et al. Formulation Engineering of Oral Semaglutide Tablets: Unleashing Gastric Intestinal Permeation with Sodium Caprate. Pharmaceutics. 2026;18(6):680. doi:10.3390/pharmaceutics18060680

BibTeX
@article{Kim2026,
  author = {Kim, Do-Hyub and Hwang, Sung-Kwan and Yoon, Ji-Hyeon and Na, Dong Hee and Park, Young-Joon and Chae, Yoon-Jee and Chang, Ji-Eun and Kim, Joo-Eun},
  title = {Formulation Engineering of Oral Semaglutide Tablets: Unleashing Gastric Intestinal Permeation with Sodium Caprate},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {6},
  pages = {680},
  doi = {10.3390/pharmaceutics18060680}
}
Kostenlos starten →